Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 284

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial

Open access
Ginzler, Ellen M, Wax, Stephen, Rajeswaran, Anand, Copt, Samuel, Hillson, Jan, Ramos, Eleanor, Singer, Nora G·2012·Arthritis Research & Therapy
DOI 10.1186/ar3738
Open this paper in CoChat — free account

Abstract

Introduction: Atacicept is a soluble, fully human, recombinant fusion protein that inhibits B cell-stimulating factors APRIL (a proliferation-inducing ligand) and BLyS (B-lymphocyte stimulator). The APRIL- LN study aimed to evaluate the efficacy and safety of atacicept in patients with active lupus nephritis (LN), receiving newly initiated corticosteroids (CS) and mycophenolate mofetil (MMF). Methods: This was a randomized, double-blind, placebo-controlled Phase II/III, 52-week study. At screening (Day -14), patients initiated high-dose CS (the lesser of 0.8 mg/kg/day or 60 mg/day prednisone) and MMF (1 g daily, increased by 1 g/day each week to 3 g daily). From Day 1, atacicept (150 mg, subcutaneously, twice weekly for 4 weeks, then weekly) was initiated with MMF along with a tapered dose of CS. Results: The trial was terminated after the enrollment of six patients, due to an unexpected decline in serum immunoglobulin G (IgG) and the occurrence of serious infections. Efficacy was thus not evaluated. By Day 1, serum IgG levels had declined substantially in patients then randomized to atacicept ( n = 4) compared with placebo ( n = 2). Patients receiving atacicept also had more severe proteinuria on Day -14 than those on placebo. Lymphocyte counts were low at screening in all patients. IgG decline continued following initiation (Day 1) of atacicept. Three atacicept-treated patients developed serum IgG below the protocol-defined discontinuation threshold of 3 g/l, two of whom developed serious pneumonia. Conclusions: Future studies are needed to characterize the safety, efficacy, and pharmacodynamic response of atacicept in LN patients. Trial Registration: ClinicalTrials.gov: NCT00573157

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/ar3738

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 284

Metadata

Authors
Ginzler, E. M., Wax, S., Rajeswaran, A., Copt, S., Hillson, J., Ramos, E., & Singer, N. G.
Venue
Arthritis Research & Therapy
Publisher
Springer Science and Business Media LLC
Published
2012-02-07
Volume
14
Issue
1
Pages
R33-R33
ISSN
1478-6354 (ISSN-L)
DOI
10.1186/ar3738
OpenAlex
W2161537704
Cited by
284
References
9
FWCI
23.73
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. https://app.cochat.ai/papers/10.1186/ar3738
The paper
Ginzler, E. M., Wax, S., Rajeswaran, A., Copt, S., Hillson, J., Ramos, E., & Singer, N. G. (2012). Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Research & Therapy. https://doi.org/10.1186/ar3738

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.